Eisai To Have SFJ Pharma Do Phase III Trial Of Thyroid Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Eisai said it would turn over Phase III trials of a thyroid cancer drug to SFJ Pharmaceuticals, a U.S.-based biotechnology company